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We previously demonstrated that in vivo engagement of 
CD137, a member of TNF receptor superfamily, can delete 
allorective CD4
＋ T cells through the induction of activa-
tion-induced cell death (AICD) in chronic graft-versus-host 
disease (cGVHD) and subsequently reverse established 
cGVHD. In this study, we further showed that agonistic an-
ti-CD137 mAb was highly effective in triggering AICD of do-
nor CD8
＋ T cells as well as donor CD4
＋ T cells in the 
C57BL/6→unirradiated (C57BL/6 × DBA/2)F1 acute 
GVHD model. Our results suggest that strong allostimulation 
should facilitate AICD of both alloreactive CD4
＋ and CD8
＋ 
T cells induced by CD137 stimulation. Therefore, depletion 
of pathogenic T cells using agonistic anti-CD137 mAb com-
bined with potent TCR stimulation may be used to block au-
toimmune or inflammatory diseases mediated by T cells. 
[Immune Network 2011;11(6):428-430]
CD137 is a member of the TNF receptor family and functions 
as a costimulatory molecule for T cells (1). Engagement of 
CD137 using anti-CD137 mAbs has been shown to effectively 
eradicate established tumors mainly through activation of CD8
＋ 
T  cells  (1).  Paradoxically,  however,  anti-CD137  mAbs  have 
strong  immunosuppressive  effects  on  a  variety  of  auto-
i m m u n e  o r  i n f l a m m a t o r y  d i s e a s e s  t h a t  a r e  b e l i e v e d  t o  b e  
mediated mainly by CD4
＋ T cells (2). A consensus on how 
stimulation of CD137 prevents disease has yet to emerge, but 
CD137  appears  to  be  involved  in  the  hyperactivation  of  T 
cells, causing them to acquire regulatory capacity or induce 
cell  death  (3).
    In the DBA/2→unirradiated (C57BL/6 × DBA/2)F1 (BDF1) 
chronic graft-versus-host disease (cGVHD) model, anti-CD137 
mAb is highly effective in inhibiting cGVHD by deleting do-
nor CD4
＋ T cells which are required for breaking host B-cell 
tolerance (4). In a more clinically relevant cGVHD model, an-
ti-CD137 mAb reverses skin fibrosis, ulceration, and alopecia, 
a dominant feature of cGVHD, ultimately improving a general 
health condition (5). The reversal is associated with increased 
apoptosis of donor CD4
＋ T cells. The Fas death pathway is 
required  for  activation-induced  cell  death  (AICD)  of  allor-
eactive  CD4
＋ T  c e l l s .
    In this study, we hypothesized that anti-CD137 mAb might 
induce AICD of alloreactive CD8
＋ T cells as well as CD4
＋ 
T cells if they received strong allostimulation. We chose the 
C57BL/6→unirradiated  BDF1  acute  GVHD  (aGVHD)  model 
as a model system to test this hypothesis, since strong alloim-
munity for donor CD4
＋ and CD8
＋ T cells occurs in this dis-
ease  model.  BDF1  mice  received  C57BL/6  T  cells  and  an-
ti-CD137 mAb (3H3) immediately after the cell transfer. FACS 
analysis showed that there was a marked increase in apopto-
sis of both splenic CD4
＋ and CD8
＋ T cells in anti- CD137- 
treated mice 5 days after the cell transfer (Fig. 1A). A majority 
of  donor  CD4
＋  and  CD8
＋ T  cells  expressed  low  levels  of 
CD62L in both control Ig- and anti-CD137-treated mice (Fig. 
1B), indicating that AICD caused their apoptosis following in-
jection  of  anti-CD137  mAb,  as  seen  previously  (4).  At  this 
time point, a higher percent of donor CD4
＋T cells underwent 
activation  and  apoptosis  following  administration  of  an-Deletion of Donor T Cells by Anti-CD137 mAb
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Figure 1. Anti-CD137 mAb induces apoptosis of both donor CD4
+
and CD8
+ T cells in aGVHD. aGVHD was induced by transferring
5×10
7 C57BL/6 spleen/lymph node cells into BDF1 mice. Im-
mediately thereafter, anti-CD137 mAb or control Ig (200μg per 
mouse) was injected. Splenocytes were analyzed by flow cytometry 
5 days after parental cell transfer. (A) Percent of Annexin V
+ donor 
CD4
+ and CD8
+ T cells. (B) Percent of CD62L
low donor CD4
+ and 
CD8
+ T cells. n=3 mice per group. **p＜0.01 and ***p＜0.001 
between the 2 groups.
Figure 2. Anti-CD137 mAb completely blocks aGVHD. aGVHD was induced by transferring 5×10
7 C57BL/6 spleen/lymph node cells into BDF1 
mice. Immediately thereafter, anti-CD137 mAb or control Ig (200μg per mouse) was injected (n=10 per group). (A) Changes of body weight.
*p＜0.05 and ***p＜0.001 between the 2 groups at the indicated time points. (B) Survival curve. **p＜0.05 between the 2 groups. 
ti-CD137 mAb, as compared with donor CD8
＋ T cells (Fig. 
1). This result may indicate that donor CD4
＋ T cells had a 
more rapid kinetics for their activation and subsequent AICD 
in  response  to  anti-CD137  mAb.
  A long-term observation demonstrated that control Ig-treated 
mice experienced severe loss of body weight and their mor-
tality rate was high (70%), whereas anti-CD137-treated mice 
maintained normal body weight and stayed healthy until the 
termination of experiments (Fig. 2). FACS analysis for spleno-
cytes  showed  that  administration  of  anti-CD137  mAb  pre-
vented severe lymphodepletion in the spleen, a parameter for 
aGVHD (Table I). Anti-CD137-mediated inhibition of aGVHD 
was due to the deletion of donor CD4
＋ and CD8
＋ T cells 
and a subsequent failure of donor cell engraftment (Table I).
    In two preclinical models of cGVHD, now it is clear that 
agonistic anti-CD137 mAb has the ability to delete pathogenic 
alloreactive CD4
＋ T cells and autoreactive B cells. However, 
there is evidence showing that agonistic anti-CD137 mAb can 
delete antigen-specific CD8
＋ T cells as well as CD4
＋ T cells 
in vivo (6,7). Earlier treatment with agonistic anti-CD137 mAb 
maintains elevated levels of TNF-α in lymphocytic choriome-
ningitis virus (LCMV)-infected mice, leading to Fas expression 
on activated CD8
＋T cells and this in turn results in Fas-medi-
ated apoptosis (6). Even though Fas-mediated death signal is 
not sufficient to delete LCMV antigen-specific CD8
＋ T cells, 
STAT3  activation  by  signaling  through  CD137  in  dendritic Deletion of Donor T Cells by Anti-CD137 mAb 
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Table I. Inhibition of donor cell engraftment by anti-CD137 mAb
a
Group
Total
slenocytes
Number (percentage) of host cells
B cells CD4
＋ T cells CD8
＋ T cells
Control lg 24.91±0.43    0.40±0.43    2.29±1.79      0.75±0.78
  (1.73±0.7)   (4.38±1.69)     (3.35±1.65)
Anti-CD137    110±31.76  63.15±18.35  18.49±4.74    15.24±4.51
(55.64±1.94) (16.53±1.48) (13.245±1.27)
Number (percentage) of donor cells
Total cells B cells CD4
＋ T cells CD8
＋ T cells
Control lg  22.19±23.14  17.61±18.81  10.46±10.37    17.8±18.31
(88.31±4.61 (76.24±7.85) (48.56±3.73) (80.96±1.35)
Anti-CD137    4.24±22.77    0.02±0.01           0            0
  (4.40±1.89)   (0.48±0.19)   (0.17±0.10)    (0.72±0.64)
aaGVHD was induced by transferring 5×10
7 C57BL/6 spleen/lymph node cells into BDF1 mice. Immediately theafter, mice received
control lg or anti-CD137 mAb (200 μg per mouse). Splenocytes were analyzed by flow cytometry 44 days after disease induction. 
Absolute number or percent of donor cells were counted by staining splenocytes with anti-H-2K
b plus anti-B220, anti-CD4 or anti-CD8 
mAbs. 
bValues for total splenocytes and lymphocyte subsets are shown as (mean±SD)×10
-6 (n=10 mice per group).
cells is required for their complete AICD (7). In this study, 
we showed that agonistic anti-CD137 mAb could completely 
delete not only donor CD4
＋ T cells but also CD8
＋ T cells 
in  the C57BL/6→BDF1  aGVHD  model.  As  seen  in  cGVHD 
(4,5) it is likely that engagement of CD137 provides strong 
costimulatory signaling leading to AICD for donor CD4
＋and 
CD8
＋ T cells that receive sustained allostimulation during the 
evolution of aGVHD. It remains to be elucidated whether oth-
er  host  hematopoietic  and/or  nonhematopoietic  cells  are 
needed  for  AICD  of  donor  T  cells  by  agonistic  anti-CD137 
mAb  in  GVHD.
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